^
    Back
    Association details:
    Biomarker:FGFR1 expression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Truseltiq (infigratinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers

    Excerpt:
    FGFR1 expression associates with BGJ398 sensitivity in HNSCC cell lines and predicts tyrosine kinase inhibitor sensitivity in PDXs.
    DOI:
    10.1158/1078-0432.CCR-14-3357